You are viewing: Switzerland Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The Switzerland Leukapheresis Market was valued at $0.65 Million in 2026 and projected to reach to $0.88 Million by 2031, representing a compound annual growth rate of CAGR 6.1%. Switzerland's leukapheresis market demonstrates steady growth driven by increasing adoption of CAR-T cell therapies and advanced hematologic treatments.

Switzerland Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Switzerland Leukapheresis Market Trends and Insights

  • Switzerland's advanced healthcare infrastructure and high adoption of cell therapy technologies support steady market expansion.
  • The country's strong regulatory framework and investment in hematologic and oncologic treatments drive demand for leukapheresis procedures. In Switzerland, the leukapheresis market benefits from increasing prevalence of blood cancers and growing clinical applications in CAR-T cell therapy and other immunotherapies.
  • Switzerland's healthcare system prioritizes access to cutting-edge therapeutic technologies, positioning the nation as a key market for apheresis equipment and services.
  • Between 2026 and 2031, Switzerland is expected to see incremental adoption driven by expanding treatment protocols and improved reimbursement pathways. The Swiss market reflects Europe's broader trend toward personalized medicine and cell-based therapies.
  • Switzerland's commitment to healthcare innovation and patient outcomes ensures continued investment in leukapheresis infrastructure and clinical capabilities through the forecast period..

Key Market Statistics

  • CAGR (2026-2031) CAGR 6.1%
  • Market Size, 2026 ~USD 0.65 Million
  • Forecast, 2031 ~USD 0.88 Million
  • Country Switzerland

Switzerland Leukapheresis Market Overview

Market Size & Growth :

Switzerland's leukapheresis market is valued at $0.65 million in 2026, expanding to $0.88 million by 2031 at a CAGR of 6.1%, outpacing many European peers due to advanced healthcare infrastructure.

Advanced Healthcare Infrastructure :

Switzerland's world-class medical facilities and high healthcare spending per capita create an ideal environment for adoption of sophisticated leukapheresis technologies and cell therapy innovations.

Strong Regulatory Framework :

Switzerland's robust regulatory environment and alignment with European standards facilitate rapid approval and implementation of advanced leukapheresis devices and protocols in clinical settings.

Cell Therapy Leadership :

Significant investment in hematologic and oncologic treatments positions Switzerland as a leader in cell therapy adoption, driving demand for specialized leukapheresis equipment and services.

Switzerland Leukapheresis Market Dynamics

  • The country's premium healthcare system and high patient access to innovative oncology solutions support consistent market expansion through 2031.
  • Switzerland's emphasis on precision medicine and personalized cancer treatment protocols creates sustained demand for leukapheresis procedures. The market benefits from Switzerland's strong pharmaceutical and biotech sector, with numerous research institutions and hospitals investing in cell therapy capabilities.
  • Continued healthcare modernization, coupled with rising incidence of hematologic malignancies and growing awareness of cell-based therapies, will sustain market growth.
  • Strategic partnerships between Swiss healthcare providers and international cell therapy manufacturers are expected to further accelerate market penetration..

Related Ecosystem

Key Takeaways

  • Switzerland's leukapheresis market is valued at $0.65 million in 2026 and will reach $0.88 million by 2031 at a 6.1% CAGR.
  • Switzerland's advanced healthcare system and regulatory environment support adoption of cell therapy and apheresis technologies.
  • Growing prevalence of hematologic malignancies and CAR-T cell therapy applications drive market growth in Switzerland.
  • Switzerland's commitment to personalized medicine and healthcare innovation ensures sustained investment in leukapheresis infrastructure through 2031.

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

Switzerland Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

SWITZERLAND: LEUKOPAKS MARKET, BY END USER, 2024–2031

Segment20242025202620272028202920302031CAGR (%)
ACADEMIC & RESEARCH INSTITUTES4.294.645.045.475.966.57.117.799.1
CONTRACT RESEARCH ORGANIZATIONS0.220.230.240.260.270.290.310.336.7
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES1.181.291.421.571.731.922.132.3610.7
TOTAL5.686.166.77.37.968.719.5510.499.4

SWITZERLAND: LEUKAPHERESIS MARKET, BY END USER, 2024–2031

Segment20242025202620272028202920302031CAGR (%)
ACADEMIC & RESEARCH INSTITUTES0.10.110.120.120.130.140.140.155.7
BLOOD COMPONENT PROVIDERS & BLOOD CENTERS0.360.390.420.450.480.510.550.597.2
HOSPITALS & TRANSFUSION CENTERS0.190.210.220.230.250.260.280.36.5
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES0.060.070.070.070.070.080.080.094.6
TOTAL0.720.770.820.870.930.991.061.136.6

Target Audience

  • Medical Device Manufacturers : Leukapheresis equipment and cell therapy device manufacturers need Switzerland-specific market data to assess market potential, identify distribution partners, and develop localized product strategies.
  • Healthcare Providers & Hospitals : Swiss hospitals and cancer treatment centers require market insights to justify capital investments in leukapheresis technology, benchmark against peers, and plan cell therapy program expansion.
  • Pharmaceutical & Biotech Companies : Cell therapy developers and CAR-T manufacturers need Switzerland market intelligence to understand treatment adoption rates, reimbursement landscapes, and clinical demand for leukapheresis services.
  • Healthcare Investors & Consultants : Investment firms and management consultants require Switzerland-specific market data to evaluate healthcare technology opportunities, assess portfolio companies, and guide strategic acquisitions.
  • Healthcare Policy & Regulatory Bodies : Swiss healthcare authorities and policy makers need market analysis to inform reimbursement decisions, technology assessment, and healthcare infrastructure planning for advanced cell therapies.

Key Companies in the Switzerland Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

Reasons to Buy this Report

  • Precise Market Sizing : Obtain Switzerland-specific market valuations ($0.65M in 2026, $0.88M in 2031) with accurate CAGR projections to support investment decisions and business planning in this premium healthcare market.
  • Regulatory & Compliance Insights : Understand Switzerland's unique regulatory landscape and healthcare approval processes to navigate market entry strategies and ensure compliance with Swiss and European standards.
  • Competitive Landscape Analysis : Identify key players, market dynamics, and competitive positioning specific to Switzerland's leukapheresis sector to inform go-to-market strategies and partnership opportunities.
  • Growth Driver Identification : Analyze Switzerland-specific factors driving 6.1% CAGR, including healthcare infrastructure investments, cell therapy adoption rates, and oncology treatment trends to capitalize on market opportunities.
  • Strategic Market Intelligence : Access actionable insights on Swiss healthcare provider preferences, reimbursement models, and technology adoption patterns to optimize product positioning and sales strategies.

Frequently asked questions

What is the current size of the leukapheresis market in Switzerland?

Switzerland's leukapheresis market is estimated at $0.65 million in 2026 and is expected to grow to $0.88 million by 2031.

What is the projected growth rate for leukapheresis in Switzerland?

Switzerland's leukapheresis market is projected to grow at a compound annual growth rate (CAGR) of 6.1% from 2026 to 2031.

What factors drive leukapheresis market growth in Switzerland?

Key drivers in Switzerland include increasing prevalence of blood cancers, expanding CAR-T cell therapy applications, advanced healthcare infrastructure, and strong regulatory support for cell-based therapies.

How does Switzerland's healthcare system support leukapheresis adoption?

Switzerland's advanced healthcare infrastructure, high healthcare spending, robust regulatory framework, and commitment to personalized medicine create a favorable environment for leukapheresis technology adoption and clinical implementation.

What is the forecast market size for leukapheresis in Switzerland by 2031?

Switzerland's leukapheresis market is forecasted to reach $0.88 million by 2031, representing growth of $0.23 million from the 2026 baseline.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status